Digest Network Come funziona
Network
/
Società
Vi
Non verificato

Vir Biotechnology, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaHIV, AIDS e malattie autoimmuniMedicina - VarieSalute

47 comunicati stampa

Guarda tutti i comunicati
12/01/2026
Scienza
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Oncologia
Web e Social Network
Mercato del lavoro
Fiere
Eventi
Analisi di mercato
Finanza
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0
05/01/2026
Scienza
Medicina - Varie
Biologia
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Eventi
Web e Social Network
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0
16/12/2025
Mercato del lavoro
Industria
Scienza
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Sanità
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0
19/11/2025
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Oncologia
Eventi
Web e Social Network
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0
09/11/2025
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Eventi
Fiere
Industria
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0
07/11/2025
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Oncologia
Eventi
Web e Social Network
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0
05/11/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0
03/11/2025
Igiene alimentare
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0
22/10/2025
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0
09/10/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Industria
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0